TTM
−$1.39B
YoY change
+71.5%
5Y CAGR
—
Peak year (2017)
−$31.13M
Cumulative operating income
−$3.49B
Operating Income history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: −$1.18B
Operating Income growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: +71.5%
Operating Income history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | −$1.18B | +71.5% | −$492.85M | ||
| 2024 | −$689.52M | +41.5% | −$202.34M | ||
| 2023 | −$487.19M | +88.6% | −$228.91M | ||
| 2022 | −$258.28M | +37.4% | −$70.27M | ||
| 2021 | −$188.01M | +69.8% | −$77.31M | ||
| 2020 | −$110.70M | +104.5% | −$56.58M | ||
| 2019 | −$54.12M | +34.2% | −$13.79M | ||
| 2018 | −$40.33M | +29.6% | −$9.20M | ||
| 2017 | −$31.13M | — | — |
- 2025−$1.18B+71.5%
- 2024−$689.52M+41.5%
- 2023−$487.19M+88.6%
- 2022−$258.28M+37.4%
- 2021−$188.01M+69.8%
- 2020−$110.70M+104.5%
- 2019−$54.12M+34.2%
- 2018−$40.33M+29.6%
- 2017−$31.13M—
Operating Income values are taken from Revolution Medicines's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Revolution Medicines (RVMD)
According to Revolution Medicines's latest reported financial statements, the company's current operating income (TTM) is −$1.39B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Revolution Medicines (RVMD) most recent annual operating income stands at −$1.18B (2025) – surged 71.5% year-over-year.
The record annual operating income stands at −$31.13M, reached in 2017; the historical low of −$1.18B was recorded in 2025.
Revolution Medicines Operating Income by Year
Revolution Medicines Operating Income 2025: −$1.18B
Revolution Medicines operating income in 2025 was −$1.18B, surged 71.5% from 2024. This figure represents the lowest annual value in the available history.
Revolution Medicines Operating Income 2024: −$689.52M
2024's operating income for Revolution Medicines came in at −$689.52M, surged 41.5% from 2023.
Revolution Medicines Operating Income 2023: −$487.19M
Revolution Medicines posted operating income of −$487.19M in 2023, surged 88.6% from 2022.
Revolution Medicines Operating Income 2022: −$258.28M
In 2022, Revolution Medicines reported operating income of −$258.28M, surged 37.4% from 2021.
Revolution Medicines Operating Income 2021: −$188.01M
Revolution Medicines operating income in 2021 was −$188.01M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by Operating Income
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation